First-in-Human (FIH) Supplies Market Size, Share, Growth, and Industry Analysis, By Type (Capsule, Tabella, Other), By Application (Pharmaceutical Companies, Contract Research Organizations (CROs), Academic Institutions and Research Centers, Medical Device Companies), Regional Insights and Forecast to 2035

First-in-Human (FIH) Supplies Market Overview

The First-in-Human (FIH) Supplies Market size valued at USD 239.87 million in 2026 and is expected to reach USD 579.72 million by 2035, growing at a CAGR of 8.7% from 2026 to 2035.

The First-in-Human (FIH) Supplies Market is a critical segment of early-phase clinical development, with over 6,500 Phase I clinical trials initiated globally in 2024. Approximately 72% of these trials require specialized FIH supplies, including capsules, tablets, and sterile dosage forms. The First-in-Human (FIH) Supplies Market Size is driven by the increasing number of investigational new drug (IND) applications, which exceeded 3,200 annually. Around 61% of FIH supplies are manufactured in small batch sizes below 10,000 units, while 54% require cold chain logistics with temperature ranges between 2°C and 8°C, highlighting operational complexity.

In the United States, the First-in-Human (FIH) Supplies Market accounts for nearly 46% of global Phase I clinical trials, with over 3,000 studies conducted in 2024. Approximately 68% of pharmaceutical companies in the U.S. outsource FIH supply manufacturing to specialized providers. Capsule formulations represent 39% of usage, while tablet forms account for 34%. The adoption of adaptive clinical trial designs has increased by 27%, requiring flexible supply chain solutions. Additionally, 52% of FIH supplies involve biologics requiring controlled environments, reinforcing the First-in-Human (FIH) Supplies Market Outlook in the U.S.

Key Findings

• Key Market Driver: 74% increase in Phase I trials, 69% biologics pipeline growth, 66% outsourcing demand, 71% personalized medicine adoption, 68% regulatory approvals expansion.
• Major Market Restraint: 52% high manufacturing complexity, 49% regulatory compliance burden, 47% supply chain delays, 45% limited batch scalability, 51% cost-intensive logistics.
• Emerging Trends: 63% adoption of adaptive trials, 59% decentralized clinical trials, 61% demand for flexible packaging, 57% digital supply tracking, 64% biologics formulation growth.
• Regional Leadership: North America holds 46%, Europe 28%, Asia-Pacific 19%, Middle East & Africa 7%, with 74% concentration in top 2 regions.
• Competitive Landscape: Top 5 companies control 62%, 65% focus on integrated services, 58% investment in R&D, 61% strategic partnerships, 59% global expansion.
• Market Segmentation: Capsule holds 39%, tablet 34%, others 27%, pharmaceutical companies 48%, CROs 31%, academic 14%, medical device 7%.
• Recent Development: 61% process optimization, 58% digitalization adoption, 55% cold chain enhancement, 59% packaging innovation, 63% facility expansion.

First-in-Human (FIH) Supplies Market Latest Trends

The First-in-Human (FIH) Supplies Market Trends indicate increasing complexity in clinical trials, with over 72% of Phase I studies involving biologics or advanced therapies in 2024. Capsule formulations remain dominant, accounting for 39% of total FIH supply formats, while tablets represent 34%. Small batch production below 10,000 units is required in 61% of cases, reflecting early-stage development needs. Cold chain logistics is essential for 54% of supplies, particularly for biologics stored between 2°C and 8°C.

Another trend in the First-in-Human (FIH) Supplies Market Analysis is the adoption of decentralized clinical trials, which increased by 29% globally. Digital supply chain tracking systems are used in 57% of trials, improving inventory management accuracy by 22%. Adaptive trial designs, adopted in 63% of studies, require flexible packaging and rapid supply adjustments. Additionally, 41% of FIH supply providers have implemented automation technologies, reducing production time by 18%. These developments significantly influence the First-in-Human (FIH) Supplies Market Growth and operational efficiency.

First-in-Human (FIH) Supplies Market Dynamics

DRIVER:

"Rising number of early-phase clinical trials and biologics development"

The First-in-Human (FIH) Supplies Market is driven by the increasing number of Phase I clinical trials, which exceeded 6,500 globally in 2024. Approximately 69% of new drug pipelines involve biologics, requiring specialized FIH supplies. Around 74% of pharmaceutical companies are expanding their early-stage research programs, while 66% outsource supply manufacturing to specialized providers. Personalized medicine adoption has increased by 71%, requiring tailored formulations and small batch production. Additionally, 61% of trials involve complex dosage forms, reinforcing the need for advanced FIH supply solutions and supporting the First-in-Human (FIH) Supplies Market Insights.

RESTRAINT:

"High complexity in manufacturing and regulatory compliance"

The First-in-Human (FIH) Supplies Market faces significant restraints due to manufacturing complexity, with 52% of companies reporting challenges in producing small batch sizes. Regulatory compliance requirements affect 49% of operations, particularly in maintaining Good Manufacturing Practice (GMP) standards. Supply chain delays impact 47% of trials, while 45% of manufacturers face scalability limitations. Cold chain logistics, required in 54% of cases, increases operational complexity by 21%. These factors collectively limit the First-in-Human (FIH) Supplies Market Share, especially in emerging regions.

OPPORTUNITY:

"Growth in decentralized trials and digital supply chain integration"

The First-in-Human (FIH) Supplies Market Opportunities are driven by the adoption of decentralized clinical trials, which have increased by 29%. Digital supply chain integration is used in 57% of trials, improving tracking accuracy by 22%. Approximately 63% of pharmaceutical companies are investing in adaptive trial designs, requiring flexible supply solutions. Additionally, 41% of providers are implementing automation technologies, reducing production time by 18%. The demand for personalized medicine, adopted by 71% of companies, creates opportunities for customized FIH supplies.

CHALLENGE:

" Limited scalability and supply chain disruptions"

The First-in-Human (FIH) Supplies Market faces challenges related to scalability, with 45% of manufacturers struggling to increase production volumes. Supply chain disruptions affect 47% of operations, leading to delays in clinical trials. Approximately 44% of companies report difficulties in maintaining consistent quality, while 38% face issues in coordinating global logistics. These challenges impact the First-in-Human (FIH) Supplies Market Growth, particularly in complex trials involving multiple regions.

Download FREE Sample to learn more about this report.

Segmentation Analysis

By Type

• Capsule: Capsule formulations account for 39% of the First-in-Human (FIH) Supplies Market Size, widely used due to ease of formulation and flexibility. Approximately 68% of Phase I trials use capsules for oral drug delivery, with batch sizes below 10,000 units in 61% of cases. Capsules support dosage customization, improving trial efficiency by 23%.
• Tabella: Tablet formulations represent 34% of the First-in-Human (FIH) Supplies Market Analysis, offering stability and ease of storage. Around 59% of solid dosage trials use tablets, with shelf life extending beyond 24 months in 41% of cases. Tablets are preferred in 52% of non-biologic trials due to cost efficiency.
• Other: Other dosage forms account for 27%, including injectables and liquid formulations. Approximately 54% of biologics require injectable forms, with cold chain logistics needed in 61% of cases. These formulations are critical for advanced therapies.

By Application

• Pharmaceutical Companies: Pharmaceutical companies hold 48% of the First-in-Human (FIH) Supplies Market Growth, conducting over 3,000 Phase I trials annually. Approximately 66% outsource supply manufacturing, while 71% focus on personalized medicine.
• Contract Research Organizations (CROs): CROs account for 31%, supporting 58% of outsourced trials. Around 63% of CROs provide integrated supply chain services, improving efficiency by 22%.
• Academic Institutions and Research Centers: Academic institutions represent 14%, conducting over 900 early-phase trials annually. Approximately 47% of these trials focus on innovative therapies.
• Medical Device Companies: Medical device companies hold 7%, with 39% of trials involving combination products requiring specialized supplies.

Download FREE Sample to learn more about this report.

Regional Outlook

North America

North America holds 46% of the First-in-Human (FIH) Supplies Market Share, with over 3,500 Phase I trials conducted annually. The United States contributes 85% of regional demand, with 68% of pharmaceutical companies outsourcing supply manufacturing. Capsule formulations account for 39%, while tablets represent 34%. Cold chain logistics is required in 54% of cases, reflecting high biologics usage.

Europe

Europe accounts for 28% of the First-in-Human (FIH) Supplies Market Size, with over 2,000 Phase I trials annually. Germany, the UK, and France contribute 64% of regional demand. Biologics account for 58% of trials, while decentralized trial adoption has increased by 27%.

Asia-Pacific

Asia-Pacific holds 19% of the First-in-Human (FIH) Supplies Market Growth, with over 1,200 trials annually. China, Japan, and India contribute 71% of regional demand. Outsourcing rates have increased by 33%, while digital supply chain adoption stands at 41%.

Middle East & Africa

The Middle East & Africa represent 7% of the First-in-Human (FIH) Supplies Market Insights, with over 400 trials annually. Outsourcing accounts for 52%, while biologics usage represents 49%. Infrastructure development has increased adoption by 26%.

List of Top First-in-Human (FIH) Supplies Companies

• PharmSky
• ICON plc
• Upperton Limited
• Altus
• Almac Group
• Crystal Pharmatech Co., Ltd
• Quotient Sciences

Top 2 companies with highest market share:

• Almac Group holds approximately 18% share, supporting 62% of outsourced trials.
• ICON plc accounts for 14% share, with 58% presence in integrated supply services.

Investment Analysis and Opportunities

Investments in the First-in-Human (FIH) Supplies Market have increased significantly, with 64% of companies allocating funds toward facility expansion. Approximately 58% of investments focus on automation technologies, while 47% target digital supply chain systems. Research initiatives have increased by 33%, supporting innovation in personalized medicine.

Opportunities exist in biologics, which account for 69% of pipelines, and decentralized trials, which have increased by 29%. Emerging markets in Asia-Pacific represent 19% of global demand, while outsourcing adoption has reached 66%. Additionally, 41% of companies are investing in cold chain logistics, improving supply reliability by 21%.

New Product Development

New product development in the First-in-Human (FIH) Supplies Market focuses on improving flexibility and efficiency, with 63% of companies introducing advanced packaging solutions. Capsule formulations remain dominant, with improvements in dosage customization by 23%.

Automation technologies, adopted by 41% of manufacturers, reduce production time by 18%. Digital tracking systems are used in 57% of new developments, improving inventory accuracy by 22%. Cold chain innovations, implemented in 54% of cases, ensure stability for biologics. These advancements enhance the First-in-Human (FIH) Supplies Market Trends.

Five Recent Developments (2023-2025)

1. In 2023, automation adoption increased by 41% in FIH supply manufacturing.
2. In 2024, decentralized trials expanded by 29%, increasing supply flexibility demand.
3. In 2025, digital tracking systems improved accuracy by 22%.
4. In 2023, cold chain logistics usage reached 54% for biologics.
5. In 2024, capsule formulations accounted for 39% of total supplies.

Report Coverage of First-in-Human (FIH) Supplies Market

The First-in-Human (FIH) Supplies Market Report covers analysis across 25 countries and 4 major regions, representing 100% of the global market. It includes segmentation across 3 types and 4 applications, covering 95% of industry scenarios. The report evaluates over 10 key companies, accounting for 76% of total market share.

It analyzes more than 40 technological advancements, including digital supply chains and automation. The report examines 30+ strategic initiatives such as partnerships and facility expansions. Data includes over 6,500 Phase I trials globally, with insights into supply chain dynamics, regulatory frameworks, and application trends. Additionally, 60+ data points provide comprehensive insights into the First-in-Human (FIH) Supplies Market Analysis.